← 返回

在透明细胞肾细胞癌中恢复 VHL 可改善 NK 细胞浸润和功能

英文原题:VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function.

查看英文原题

VHL restoration in clear cell renal cell carcinoma improves NK cell infiltration and function.

PubMed 2025/07/30(内容时间) Cancer Immunol Immunother Q1 · IF 5.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

VHL 突变肿瘤由于 HIF 稳定驱动的免疫抑制通路,NK 细胞浸润较少。恢复 VHL 可重编程肿瘤微环境,减少 ccRCC 进展和免疫抑制信号,同时增强 NK 细胞浸润和激活。抑制 HIFα可改善 NK 细胞浸润至 VHL 突变肿瘤。因此,应探索抑制 HIFα作为 ccRCC 的治疗策略,以增强 NK 细胞对 VHL 突变肿瘤的抗肿瘤效果。

研究思路结论见上方概要

von Hippel-Lindau(VHL)基因在透明细胞肾细胞癌(ccRCC)中频繁突变,导致缺氧诱导因子(HIF)稳定化。尽管HIF具有众所周知的免疫抑制作用,ccRCC仍被认为是一种具有高淋巴细胞浸润的免疫原性肿瘤。由于NK细胞在ccRCC患者中具有预后价值,了解VHL突变如何影响NK细胞活性和抗肿瘤免疫非常重要。

肿瘤球由亲本786-O(VHL突变)和786-O-pVHL(VHL恢复)ccRCC细胞系生成。分别通过流式细胞术、质谱和Luminex检测分析肿瘤表型、蛋白质组和分泌组。定量蛋白质组学分析和定量基因本体富集用于将蛋白质表达变化与ccRCC进展和免疫抑制通路相关联。NK细胞浸润、活化和细胞毒性分别在ccRCC肿瘤球与健康供者NK细胞的共培养中通过实时成像、免疫染色和流式细胞术进行评估。

与VHL恢复的肿瘤球体相比,VHL突变的肿瘤球体被NK细胞浸润显著减少。浸润pVHL的NK细胞显示出活化表型,并具有缩小肿瘤球体大小的能力。蛋白质组学分析显示,VHL恢复的肿瘤中与ccRCC进展和免疫抑制相关的蛋白水平降低,包括MHC I类加工和PD-1信号传导的组分。此外,VHL恢复的肿瘤中缺氧相关和促肿瘤细胞因子水平降低,如GROα、IL-8、IL-10、TRAIL、VEGF和SCF。在768-O肿瘤球体中,NK细胞表现出更高程度的缺氧和HIF1α表达,抑制HIF1α导致NK细胞向786-O球体的浸润增加。同样,在786-O球体中抑制VHL靶基因HIF2α导致NK细胞浸润增加。

展开英文摘要原文

The von Hippel-Lindau (VHL) gene is frequently mutated in clear cell renal cell carcinoma (ccRCC) which results in stabilization of hypoxia-inducible factor (HIF). Despite the well-known immunosuppressive effect of HIF, ccRCC is considered an immunogenic tumor with high lymphocyte infiltration. Since NK cells have a prognostic value in ccRCC patients, it is important to understand how VHL mutations affect NK cell activity and anti-tumor immunity.

Tumor spheroids were generated from parental 786-O (VHL-mutated) and 786-O-pVHL (VHL-restored) ccRCC cell lines. Tumor phenotypes, proteome, and secretome were analyzed by flow cytometry, mass spectrometry, and Luminex assays, respectively. Quantitative proteomics analysis and quantitative gene ontology enrichment were used to correlate protein expression changes to ccRCC progression and immunosuppressive pathways. NK cell infiltration, activation, and cytotoxicity were assessed in co-cultures of ccRCC spheroids with NK cells from healthy donors using real-time imaging, immunostaining, and flow cytometry, respectively.

VHL-mutated tumor spheroids were significantly less infiltrated by NK cells compared with VHL-restored tumor spheroids. pVHL-infiltrating NK cells showed an activated phenotype along with the ability to reduce tumor spheroid size. Proteomic analysis revealed that VHL-restored tumors express reduced levels of proteins associated with ccRCC progression and immunosuppression, including components of MHC class I processing and PD-1 signaling. Furthermore, VHL-restored tumors exhibited decreased levels of hypoxia-related and pro-tumoral cytokines, such as GROα, IL-8, IL-10, TRAIL, VEGF, and SCF. Within 768-O tumor spheroids, NK cells displayed a higher degree of hypoxia and expression of HIF1α, and inhibition of HIF1α resulted in higher NK cell infiltration into 786-O spheroids. Similarly, inhibition of the VHL-target gene, HIF2α, in 786-O spheroids resulted in increased NK cell infiltration.

VHL mutant tumors are less infiltrated by NK cells due to immunosuppressive pathways driven by HIF stabilization. Restoration of VHL reprograms the tumor microenvironment, reducing ccRCC progression and immunosuppressive signaling while enhancing NK cell infiltration and activation. Inhibition of HIFα improves NK cell infiltration into VHL mutant tumors. Therefore, inhibition of HIFα should be explored as a therapeutic strategy in ccRCC to improve NK cell anti-tumor efficacy against VHL-mutated tumors.

论文信息

作者
Tong L、Tay AHM、Cui W、Liu Y、Su Y、Lyu J、Hoedemakers L、Yang Y
第一作者单位
Department of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden.Sweden
通讯作者单位
Department of Oncology-Pathology, Karolinska Institutet, J6:20 BioClinicum, Akademiska straket 1, Solna, 17164, Stockholm, Sweden. andreas.lundqvist@ki.se.Sweden
期刊
Cancer immunology, immunotherapy : CII2025 Jul 30
原文标识
PubMed 40736709 · DOI 10.1007/s00262-025-04132-x